244 related articles for article (PubMed ID: 32683306)
1. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile.
Ciampi E; Uribe-San-Martín R; Soler B; Fernández R; García P; Navarrete-Asenjo C; Tirapegui JM; Torres R; Polanco J; Suárez F; Cuello MJ; Cárcamo C
Mult Scler Relat Disord; 2020 Oct; 45():102392. PubMed ID: 32683306
[No Abstract] [Full Text] [Related]
2. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Ciampi E; Uribe-San-Martin R; Cárcamo C
Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203
[No Abstract] [Full Text] [Related]
3. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
[TBL] [Abstract][Full Text] [Related]
4. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
5. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Tomczak A; Han MH
Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
[TBL] [Abstract][Full Text] [Related]
6. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
[No Abstract] [Full Text] [Related]
7. Screening neuromyelitis optica patients for COVID-19 infection.
Mirmosayyeb O; Vaheb S; Barzegar M; Shaygannejad V; Bonavita S; Ghajarzadeh M
Autoimmun Rev; 2020 Nov; 19(11):102669. PubMed ID: 32942032
[No Abstract] [Full Text] [Related]
8. The COVID-19 pandemic and the use of MS disease-modifying therapies.
Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
[No Abstract] [Full Text] [Related]
9. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
10. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?
Ghajarzadeh M; Bonavita S
Neurol Sci; 2020 Sep; 41(9):2315-2316. PubMed ID: 32638135
[No Abstract] [Full Text] [Related]
11. Natural History of Asymptomatic SARS-CoV-2 Infection.
Sakurai A; Sasaki T; Kato S; Hayashi M; Tsuzuki SI; Ishihara T; Iwata M; Morise Z; Doi Y
N Engl J Med; 2020 Aug; 383(9):885-886. PubMed ID: 32530584
[No Abstract] [Full Text] [Related]
12. Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients.
Telfer P; De la Fuente J; Sohal M; Brown R; Eleftheriou P; Roy N; Piel FB; Chakravorty S; Gardner K; Velangi M; Drasar E; Shah F; Porter JB; Trompeter S; Atoyebi W; Szydlo R; Anie KA; Ryan K; Sharif J; Wright J; Astwood E; Nicolle CS; Webster A; Roberts DJ; Lugthart S; Kaya B; Awogbade M; Rees DC; Hollingsworth R; Inusa B; Howard J; Layton DM
Haematologica; 2020 Nov; 105(11):2651-2654. PubMed ID: 33054122
[No Abstract] [Full Text] [Related]
13. Impact of COVID-19 on patients with asthma.
Pignatti P; Visca D; Cherubino F; Zampogna E; Spanevello A
Int J Tuberc Lung Dis; 2020 Nov; 24(11):1217-1219. PubMed ID: 33172533
[No Abstract] [Full Text] [Related]
14. [Concepts for good decision-making in the COVID-19 pandemic in Chile].
Canals L M
Rev Chilena Infectol; 2020 Apr; 37(2):170-172. PubMed ID: 32730484
[No Abstract] [Full Text] [Related]
15. Clinical characteristics of SARS-CoV-2 infection in a rural area in Germany.
von Meißner WCG; Strumann C; Kochen MM; Blickle PG; Wölk B; Pömsl J; Fink W; Steinhaeuser J
Rural Remote Health; 2020 Sep; 20(3):6325. PubMed ID: 32955912
[No Abstract] [Full Text] [Related]
16. Follow-up of asymptomatic patients with SARS-CoV-2 infection.
Zhou X; Li Y; Li T; Zhang W
Clin Microbiol Infect; 2020 Jul; 26(7):957-959. PubMed ID: 32234453
[No Abstract] [Full Text] [Related]
17. COVID-19, impact on myeloma patients.
Dufour I; Raedemaeker J; Andreozzi F; Verstraete G; Bailly S; Delforge M; Storms P; Jacquy C; Van de Velde A; Mineur P; Lejeune M; Bauwens D; Van Obbergh F; Kentos A; Nguyen J; Fostier K; De Weweire A; Meuleman N; Vekemans MC
Ann Hematol; 2020 Aug; 99(8):1947-1949. PubMed ID: 32577846
[No Abstract] [Full Text] [Related]
18. Lung Ultrasound Evolution in a Patient with COVID-19.
Royer O; Couture EJ; Langevin S
Am J Respir Crit Care Med; 2020 Nov; 202(9):1297-1298. PubMed ID: 32976034
[No Abstract] [Full Text] [Related]
19. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients.
Lin D; Liu L; Zhang M; Hu Y; Yang Q; Guo J; Guo Y; Dai Y; Xu Y; Cai Y; Chen X; Zhang Z; Huang K
Sci China Life Sci; 2020 Apr; 63(4):606-609. PubMed ID: 32170625
[No Abstract] [Full Text] [Related]
20. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
